Your browser doesn't support javascript.
Direct derivation of human alveolospheres for SARS-CoV-2 infection modeling and drug screening.
Ebisudani, Toshiki; Sugimoto, Shinya; Haga, Kei; Mitsuishi, Akifumi; Takai-Todaka, Reiko; Fujii, Masayuki; Toshimitsu, Kohta; Hamamoto, Junko; Sugihara, Kai; Hishida, Tomoyuki; Asamura, Hisao; Fukunaga, Koichi; Yasuda, Hiroyuki; Katayama, Kazuhiko; Sato, Toshiro.
  • Ebisudani T; Department of Organoid Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan; Department of Pulmonary Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan.
  • Sugimoto S; Department of Organoid Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan.
  • Haga K; Laboratory of Viral Infection I, Department of Infection Control and Immunology, Omura Satoshi Memorial Institute & Graduate School of Infection Control Sciences, Kitasato University, Tokyo 108-8641, Japan.
  • Mitsuishi A; Department of Organoid Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan; Department of Pulmonary Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan.
  • Takai-Todaka R; Laboratory of Viral Infection I, Department of Infection Control and Immunology, Omura Satoshi Memorial Institute & Graduate School of Infection Control Sciences, Kitasato University, Tokyo 108-8641, Japan.
  • Fujii M; Department of Organoid Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan.
  • Toshimitsu K; Department of Organoid Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan.
  • Hamamoto J; Department of Pulmonary Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan.
  • Sugihara K; Department of Pulmonary Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan.
  • Hishida T; Division of Thoracic Surgery, Keio University School of Medicine, Tokyo 160-8582, Japan.
  • Asamura H; Division of Thoracic Surgery, Keio University School of Medicine, Tokyo 160-8582, Japan.
  • Fukunaga K; Department of Pulmonary Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan; Coronavirus Task Force, Keio University School of Medicine, Tokyo 160-8582, Japan.
  • Yasuda H; Department of Pulmonary Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan. Electronic address: hiroyukiyasuda@a8.keio.jp.
  • Katayama K; Laboratory of Viral Infection I, Department of Infection Control and Immunology, Omura Satoshi Memorial Institute & Graduate School of Infection Control Sciences, Kitasato University, Tokyo 108-8641, Japan; Coronavirus Task Force, Keio University School of Medicine, Tokyo 160-8582, Japan. Electr
  • Sato T; Department of Organoid Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan; Coronavirus Task Force, Keio University School of Medicine, Tokyo 160-8582, Japan. Electronic address: t.sato@keio.jp.
Cell Rep ; 35(10): 109218, 2021 06 08.
Article in English | MEDLINE | ID: covidwho-1233382
ABSTRACT
Although the main cellular target of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is thought to be alveolar cells, the absence of their tractable culture system precludes the development of a clinically relevant SARS-CoV-2 infection model. Here, we establish an efficient human alveolosphere culture method and sphere-based drug testing platform for SARS-CoV-2. Alveolospheres exhibit indolent growth in a Wnt- and R-spondin-dependent manner. Gene expression, immunofluorescence, and electron microscopy analyses reveal the presence of alveolar cells in alveolospheres. Alveolospheres express ACE2 and allow SARS-CoV-2 to propagate nearly 100,000-fold in 3 days of infection. Whereas lopinavir and nelfinavir, protease inhibitors used for the treatment of human immunodeficiency virus (HIV) infection, have a modest anti-viral effect on SARS-CoV-2, remdesivir, a nucleotide prodrug, shows an anti-viral effect at the concentration comparable with the circulating drug level. These results demonstrate the validity of the alveolosphere culture system for the development of therapeutic agents to combat SARS-CoV-2.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Drug Evaluation, Preclinical / Alveolar Epithelial Cells / SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Prognostic study Topics: Traditional medicine Limits: Humans Language: English Journal: Cell Rep Year: 2021 Document Type: Article Affiliation country: J.celrep.2021.109218

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Drug Evaluation, Preclinical / Alveolar Epithelial Cells / SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Prognostic study Topics: Traditional medicine Limits: Humans Language: English Journal: Cell Rep Year: 2021 Document Type: Article Affiliation country: J.celrep.2021.109218